Plus therapeutics announces biotech industry veteran kyle guse joins its board of directors

Houston, april 23, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, announces the appointment of kyle guse, j.d., m.b.a. to the company's board of directors where he will serve as chair of the audit committee and on the compensation committee.
PSTV Ratings Summary
PSTV Quant Ranking